fbpx

molecules of the month

maralixibat

oral gut-restricted bile acid transporter inh.

approved for cholestatic pruritis in Sep. 2021

repurposed (first patented in 1994)

The Lancet

Mirum / Pfizer / Pharmacia / Searle

Chemical structure of molecule Maralixibat Mirum Pharmaceuticals IBAT bile acid transporter inhibitor
1 min read

The Mirum Pharmaceuticals IBAT bile acid transporter inhibitor, maralixibat, has a long history, having been first patented by scientists at Searle in 1994 and published by the time Searle became part of Pharmacia in 2005. It was finally approved in Sep. 2021 for treatment of cholestatic pruritis in patients with Alagille Syndrome, and is estimated to reach annual sales of $536M by 2026, a nice success story for repurposing of old mechanisms by a biotech. The drug is a bile acid transport inhibitor, preventing enterohepatic bile acid recirculation, and was originally designed to have minimal systemic exposure after oral administration.


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: